Search peptides, terms, sources/
Research source · 1996

Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children

About this source

Kind
Research
Design
Human clinical trial
Population
Human prepubertal children with constitutional short stature, mean age 7.6 years
Sample size
7
Primary or secondary
primary
Peer review
peer reviewed
Retraction status
None known
Date checked
14 November 2026

Limitations

Seven children, no control group, so the change in growth rate cannot be attributed to hexarelin. Natural growth, other factors and chance are not ruled out.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.